Fairvalue-Calculator Fairvalue-Calculator
EN DE

Alibaba Health Information Technology Limited (ALBBY) Fair Value & Analysis

Healthcare · US · Market cap $7.2B

Price$8.56
Fair Value$6.91
Upside-19.2%
Quality97/100
Evidence: High Range $4.45 – $11.85

Analysis

Alibaba Health Information Technology Limited (ALBBY) currently trades at $8.56, while our model-based Fair Value estimate is $6.91 — implying the stock looks roughly 19.2% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asse…

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +404% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +5% Clicks Group (CLCGY) +23% Sugi Holdings (SGIPF) +295% Corporativo Fragua, S.A. (CGSBF) +37%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.